
- Volume 0 0
FDA ISSUES ALERTS ON ANTIDEPRESSANT AND MIGRAINE DRUGS
The FDA has asked makersof antidepressants tomodify their labels toinclude data about a rarebut life-threatening lungproblem—persistent pulmonary hypertension—that can affect babies born towomen who take the drugs while pregnant.The agency also issued an alertabout the potential risk of combining antidepressantswith common migrainedrugs. The alert warns that a life-threateningcondition called serotonin syndromemay occur when the drugs are combined.
The FDA is investigating additionalinformation on both risks and will issuefurther updates on the drugs' labels asinformation becomes available. "It isimportant to emphasize that the FDArecommends that women who areexpecting and currently taking antidepressantsshould not discontinue usewithout first talking with a doctor," saidSusan Bro, an FDA spokeswoman.
Articles in this issue
over 19 years ago
Pharmacy Technology Productsover 19 years ago
Tobacco Useover 19 years ago
Rx Product Newsover 19 years ago
OTC Product Newsover 19 years ago
can you READ theseRxs?over 19 years ago
Generic Times Product Newsover 19 years ago
compoundingHOTLINEover 19 years ago
Compounding for Pediatric Patientsover 19 years ago
Vaccinations: Current Research and Perceptionsover 19 years ago
Police and Drug TestingNewsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

















































































































































































































